Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at JMP Securities

JMP Securities restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note released on Friday, TipRanks reports. They currently have a $40.00 price target on the stock.

Several other equities research analysts have also recently commented on the stock. BTIG Research reiterated a buy rating and set a $44.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, August 31st. Truist started coverage on shares of Taysha Gene Therapies in a report on Thursday, June 24th. They set a buy rating and a $60.00 price objective for the company. Zacks Investment Research cut shares of Taysha Gene Therapies from a hold rating to a sell rating in a report on Friday, August 20th. Chardan Capital decreased their price objective on shares of Taysha Gene Therapies from $67.50 to $60.00 and set a buy rating for the company in a report on Tuesday, August 17th. Finally, Morgan Stanley decreased their price objective on shares of Taysha Gene Therapies from $43.00 to $39.00 and set an overweight rating for the company in a report on Wednesday, August 18th. One analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of Buy and an average price target of $44.31.

Shares of NASDAQ:TSHA opened at $20.04 on Friday. Taysha Gene Therapies has a one year low of $15.50 and a one year high of $33.35. The company has a 50 day moving average of $18.77 and a 200-day moving average of $21.37. The stock has a market cap of $769.36 million and a price-to-earnings ratio of -5.89.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Monday, August 16th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). On average, sell-side analysts anticipate that Taysha Gene Therapies will post -4.04 EPS for the current year.

In other Taysha Gene Therapies news, CFO Kamran Alam sold 11,193 shares of the company’s stock in a transaction on Wednesday, August 18th. The shares were sold at an average price of $17.35, for a total transaction of $194,198.55. Following the sale, the chief financial officer now directly owns 319,928 shares of the company’s stock, valued at $5,550,750.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 41.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its position in Taysha Gene Therapies by 75.1% during the second quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock worth $32,000 after acquiring an additional 657 shares in the last quarter. Citigroup Inc. raised its position in Taysha Gene Therapies by 138.0% during the second quarter. Citigroup Inc. now owns 1,371 shares of the company’s stock worth $29,000 after acquiring an additional 795 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Taysha Gene Therapies by 140.0% during the second quarter. Ameritas Investment Partners Inc. now owns 1,745 shares of the company’s stock worth $37,000 after acquiring an additional 1,018 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Taysha Gene Therapies by 8.9% in the first quarter. Millennium Management LLC now owns 21,125 shares of the company’s stock valued at $429,000 after purchasing an additional 1,725 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Taysha Gene Therapies by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 26,223 shares of the company’s stock valued at $532,000 after purchasing an additional 2,475 shares during the last quarter. 46.07% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome.

Featured Article: What are high-yield dividend stocks?

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.